ACT-AEC 2024 Fall Meeting
Quebec City, QC
October 9th – 10th 2024
The ACT-AEC consortium met in Quebec City in October to discuss the clinical trials landscape.
Highlights of the meeting included:
- Exploring strategies to foster a vibrant Canadian biotechnology ecosystem
- Updates on the work of our ACT committees
- Discussions about regulatory processes in Canada
- PONTIAK – Prevention of NephroToxin Induced Acute Kidney Injury Trial
- PVC-RAM-2 – Post discharge after surgery Virtual Care with Remote Automated Monitoring technology 2 Trial
- LEADS – Liberation from mechanical ventilation using Extubation Advisor Decision Support: The multicentre Pilot Trial
- PERIOP:06 – A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients with Metastatic Colorectal Adenocarcinoma within the Liver Undergoing Resection
- EQUAL Dialysis – Evaluation of Qidni Urea And metabolite cLearance in maintenance Dialysis
- AMT-143: A Phase 1 Randomized Controlled Trial Evaluating AMT-143 in Healthy Volunteers to Assess Sustained Analgesic Release for Non-Opioid Pain Treatments
- CANUCS – Canadian Collaborative on Urgent Care Surgery
- CYMH – Canadian Network for Child and Youth Mental Health Trials
- PIRN – Canadian Paediatric Inpatient Research Network
- CanHMVr – The Canadian Home Mechanical Ventilation Research Network
- CCARE – LTC – Collaborative for Caring for Long-Term Care
- CMCN – Canadian Medical Cannabis Clinical Trials Network
ACT-AEC 2023 Fall Meeting
Prince Edward Island Convention Centre – Charlottetown, PEI
September 21st – 22nd 2023
ACT-AEC recently convened for our much-anticipated Fall Meeting. Over the two days, we heard from our 20 Portfolio Hospitals, RFA1 winners, and RFA2 winners. We had exciting keynote speakers and interactive break out sessions focused on discussing regulatory changes to ICH E6 R3 and a single national research ethics board process. We were pleased to have representation from our 11 Clinical Trial Units, 28 Research Networks, 20 Portfolio Hospitals, RFA winners, Patient Partners, trialists, students, sponsors, and industry. This event provided a unique environment where professionals from diverse fields of clinical research shared knowledge and fostered new connections to drive clinical trials and healthcare innovation forward. To encourage ongoing engagement and strengthen our collaborative efforts, we invite you to access the valuable meeting materials provided below:
ACT Portfolio Program 2023:
Queen Elizabeth Hospital (QEH), Charlottetown, PE
Medicine Hat Regional Hospital (MHRH), Medicine Hat, AB
East Kootenay Regional Hospital (EKRH), Cranbrook, BC
Kelowna General Hospital (KGH), Kelowna, BC
Nanaimo Regional General Hospital(NRGH), Nanaimo, BC
Penticton Regional Hospital (PRH), Penticton, BC
Dr. Georges-L.-Dumont University Hospital Centre (DGLDUHC), Moncton, NB
Cape Breton Regional Hospital (CBRH), Sydney, NS
Qikiqtani General Hospital,Iqaluit, NU
Cambridge Cardiac Care, Cambridge, ON
Health Sciences North (HSN), Sudbury, ON
Niagara Health, St. Catharines, ON
Humber River Health (HRH), North York, ON
Mackenzie Health, Richmond Hill, ON
Windsor Regional Hospital (WRH), Windsor, ON
Hôtel-Dieu de Lévis (HDL),Lévis,QC
Speakers and Panels:
Update on Accelerating Clinical Trials (ACT) Consortium and goals of meeting
Dr. P.J. Devereaux and Dr. Guy Rouleau
Co-Chairs, ACT Operations Committee
NIHRClinical Research Network
Nick Lemoine
Head of Medical Directorate
Guidance for Good Randomized Clinical Trials
Nick Medhurst
ICHE6(R3): Overview of key goals and components of draft guideline and Health Canada’s perspective
Kathy Soltys
Health Canada
Perspectives on changes to ICH (R3) Panel discussion
Margaret Mooney
National Institutes of Health
Building Capacity for Research in Community Hospitals in Canada – RICH-Canada Program
Jennifer Tsang
Niagara Health
Update from ACT Training Committee
Shrikant Bangdiwala and Bruno Battistini
Potential models for a single national REB system in Canada Panel Discussion
ACT-AEC First Annual Meeting
At the ACT-AEC First Annual Meeting, ACT-AEC invited 48 Canadian biotechnology companies to present their work to members of the consortium. ACT-AEC is proud to share the experiences of these companies in connecting with ACT-AEC’s consortium partners. To connect with ACT-AEC, contact us.
